Article Published in Drug Discovery Today
Open Orphan PLC (ORPH.L) Article published in Drug Discovery Today
Open Orphan PLC (ORPH.L) Expansion of volunteer recruitment centres
Expansion of volunteer recruitment centres for human challenge trials Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and the world leader in vaccine
Open Orphan PLC (ORPH.L) First volunteer dosed in COVID-19 clinical trial
First volunteer dosed in intran asal COVID-19 vaccine clinical trial
Open Orphan PLC (ORPH.L) Contract renewal with top-3 pharmaceutical client
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract
Open Orphan PLC (ORPH.L) Rule 19.6(c) Confirmation
RULE 19.6(c) CONFIRMATION WITH RESPECT TO STATED POST-OFFER INTENTIONS WITH REGARD TO HVIVO PLC
Open Orphan PLC (ORPH.L) Successful completion of toxicology study
Successful completion of PrEP Biopharm Toxicology study for respiratory ‘viral mimic’
Open Orphan PLC (ORPH.L) Contract renewal with top-3 pharmaceutical client
Successful extension of contract underpins 2021 revenue growth expectations
Open Orphan PLC (ORPH.L) MHRA approval for nasal COVID-19 vaccine trial
Cathal Friel, Executive Chairman of Open Orphan, said: We are delighted to announce, further to our announcement in July, the Codagenix intranasal, single dose COVID-19 vaccine candidate has received MHRA
Open Orphan PLC (ORPH.L) Venn Life Sciences contract wins
This RNS announces two very exciting deals that our Open Orphan subsidiary Venn Life Sciences has been awarded, from both our Paris office and Breda office in the Netherlands.
Open Orphan PLC (ORPH.L) Collaboration with HIC-VAC and Wellcome Trust
Open Orphan, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to
Open Orphan PLC (ORPH.L) New £2.5m Influenza Challenge Study Contract Win
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is
